Nanostics

ClarityDX Prostate is a blood-based diagnostic test that provides a risk score based on clinical and biological biomarkers to help patients and their physicians make an informed decision after an elevated PSA test result. Nanostics is a medical device and biotechnology company with a mission to provide clarity to people about their health by enabling better diagnosis and improving health care decisions through machine learning and extracellular vesicle detection. John Lewis is the Bird Dogs Chair in Translational Oncology at the University of Alberta, Edmonton, Alberta. Lewis is the co-founder of Innovascreen Inc., a successful preclinical CRO in operation since 2005, and the founder and CEO of Entos Pharmaceuticals Inc., a clinical-stage biotechnology company developing genetic medicines, incorporated in 2007. Desmond Pink is the lead researcher in the development and validation of the Nanostics diagnostics platform and has considerable expertise in scientific team management, biochemistry, protein synthesis, and experimental therapeutics. Robert Paproski is the co-founder and Chief Technology Officer of Nanostics, which develops medical devices using machine learning models. Paproski has developed expertise in laboratory assay development and computational analysis. Paproski oversees machine learning and software development, and regulatory compliance for software products.